Compare Equinix Inc (EQIX) vs Globus Medical Inc. Class A Common Stock (GMED) Price & Performance

Equinix (EQIX) trades at $1,019.40, down 1.28% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported revenue growth to $9.22B in 2025 with a net income margin of 15.63%, though recent quarters show mixed earnings performance with two misses and one beat. Analyst consensus remains strongly bullish with 75% buy ratings and a $1,250 price target, while the company continues expanding its AI-driven data center capacity with $5B-$7B annual investments.

EQIX presents growth potential through AI infrastructure demand and interconnection services, supported by strong institutional backing. However, elevated valuation ratios (P/E 64.09, P/S 10.02) and substantial capital expenditures creating negative cash flow pose risks. The stock's outlook depends on successful execution of expansion plans and maintaining premium pricing power in the competitive data center REIT sector.

Globus Medical (GMED) trades at $76.32, showing minimal daily movement with a 0.1% gain. The stock demonstrates strong fundamental performance with consistent earnings beats in recent quarters and robust profitability metrics including 68.55% gross margins and 17.03% net income margins. Technical indicators suggest neutral positioning near key support at $73 with resistance at $74. Recent developments include new product showcases at industry conferences and upcoming Q3 earnings release.

GMED presents a compelling investment case with strong analyst support (72% buy rating) and 25% upside to consensus target of $95.13. The company maintains solid revenue growth trajectory and debt-free balance sheet, though investors should monitor competitive pressures in medical devices and potential margin compression as revenue scales. Near-term catalysts include Q3 earnings results expected November 5, 2026.